Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review.
Ana Julia Aguiar de FreitasRhafaela Lima CausinMuriele Bertagna VaruzzaCassio Murilo Trovo Hidalgo FilhoVinicius Duval da SilvaCristiano de Pádua SouzaMárcia Maria Chiquitelli MarquesPublished in: Cancers (2021)
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new "OMICS" technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- lymph node
- rectal cancer
- sentinel lymph node
- transcription factor
- squamous cell carcinoma
- single cell
- radiation therapy
- small molecule
- end stage renal disease
- phase ii study
- ejection fraction
- minimally invasive
- newly diagnosed
- high throughput
- chronic kidney disease
- healthcare
- high resolution
- clinical trial
- combination therapy
- young adults
- peritoneal dialysis
- smoking cessation
- percutaneous coronary intervention
- open label
- patient reported outcomes